In the oral surveillance study, RA patients aged ≥50 years with one additional cardiovascular risk factor who were receiving tofacitinib 10 mg two times daily had an increased risk for lung cancer compared with those receiving TNF inhibitors. This evidence concerns the gene TNF and rheumatoid arthritis.